Adnane L - Search Results

1

Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity.

Wilhelm SM, Dumas J, Adnane L, Lynch M, Carter CA, Schütz G, Thierauch KH, Zopf D. Wilhelm SM, et al. Among authors: adnane l. Int J Cancer. 2011 Jul 1;129(1):245-55. doi: 10.1002/ijc.25864. Epub 2011 Apr 22. Int J Cancer. 2011. PMID: 21170960 Free article.

2

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis.

Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, Adnane L, Lynch M, Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post LE, Bollag G, Trail PA. Wilhelm SM, et al. Among authors: adnane l. Cancer Res. 2004 Oct 1;64(19):7099-109. doi: 10.1158/0008-5472.CAN-04-1443. Cancer Res. 2004. PMID: 15466206

3

Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling.

Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM, Lynch M. Wilhelm SM, et al. Among authors: adnane l. Mol Cancer Ther. 2008 Oct;7(10):3129-40. doi: 10.1158/1535-7163.MCT-08-0013. Mol Cancer Ther. 2008. PMID: 18852116 Review.

4

Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature.

Adnane L, Trail PA, Taylor I, Wilhelm SM. Adnane L, et al. Methods Enzymol. 2006;407:597-612. doi: 10.1016/S0076-6879(05)07047-3. Methods Enzymol. 2006. PMID: 16757355

5

Recent advances in the research and development of RAF kinase inhibitors.

Smith RA, Dumas J, Adnane L, Wilhelm SM. Smith RA, et al. Among authors: adnane l. Curr Top Med Chem. 2006;6(11):1071-89. doi: 10.2174/156802606777812077. Curr Top Med Chem. 2006. PMID: 16842147 Review.

6

Therapeutic mechanism and efficacy of the antibody-drug conjugate BAY 79-4620 targeting human carbonic anhydrase 9.

Petrul HM, Schatz CA, Kopitz CC, Adnane L, McCabe TJ, Trail P, Ha S, Chang YS, Voznesensky A, Ranges G, Tamburini PP. Petrul HM, et al. Among authors: adnane l. Mol Cancer Ther. 2012 Feb;11(2):340-9. doi: 10.1158/1535-7163.MCT-11-0523. Epub 2011 Dec 6. Mol Cancer Ther. 2012. PMID: 22147747

7

Under-Prescription of Medical Treatment for Peripheral Artery Disease in the Under 50s: A Retrospective Study.

Soudet S, Bultel L, Adnane L, Reix T, Sevestre MA. Soudet S, et al. Among authors: adnane l. Angiology. 2022 Apr;73(4):338-343. doi: 10.1177/00033197211042155. Epub 2021 Sep 5. Angiology. 2022. PMID: 34486390

8

High temperature Hall measurement setup for thin film characterization.

Adnane L, Gokirmak A, Silva H. Adnane L, et al. Rev Sci Instrum. 2016 Jul;87(7):075117. doi: 10.1063/1.4959222. Rev Sci Instrum. 2016. PMID: 27475605

9

High temperature setup for measurements of Seebeck coefficient and electrical resistivity of thin films using inductive heating.

Adnane L, Williams N, Silva H, Gokirmak A. Adnane L, et al. Rev Sci Instrum. 2015 Oct;86(10):105119. doi: 10.1063/1.4934577. Rev Sci Instrum. 2015. PMID: 26520996

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

9 results

Search Page